Evolus, Inc. reported $316M of revenue over the trailing twelve months, +14% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $316M (to Q2 2026). Net income: −$34M, trailing twelve months to Q2 2026. Free cash flow: −$18M, trailing twelve months to Q2 2026. Operating margin: −6.7%, trailing twelve months to Q2 2026.

EOLSEvolus, Inc.

Healthcare

$7.79+24% 1Y

$7.79

$3.9452 weeks$9.30

EOLS as reported

Evolus, Inc. reported $316M of revenue over the trailing twelve months, +14% on the year before. 10 reported series are charted on this page, each one as filed.

$316M

Revenue, trailing twelve months · to Q2 2026 · +14% against the twelve months before

Net income: −$34M
Net income · −45% year on year · trailing twelve months to Q2 2026
Free cash flow: −$18M
Free cash flow · −58% year on year · trailing twelve months to Q2 2026
Operating margin: −6.7%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for EOLS, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$316M	+14%	Q2 2026
Net income	−$34M	−45%	Q2 2026
EPS	−$0.52	−46%	Q2 2026
Gross margin	67%	n/a	Q2 2026
Operating margin	−6.7%	n/a	Q2 2026
Net margin	−12%	n/a	Q2 2026
ROE	172%	n/a	Q2 2026
ROA	−21%	n/a	Q2 2026
ROIC	−31%	n/a	Q2 2026
Free cash flow	−$18M	−58%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.